Cefepime Dosing for UTI
For mild to moderate UTI, use cefepime 0.5-1 g IV every 12 hours for 7-10 days; for severe UTI or pyelonephritis, use 2 g IV every 12 hours for 10 days. 1
Dosing Algorithm by UTI Severity
Mild to Moderate UTI (Uncomplicated or Complicated)
- Dose: 0.5-1 g IV every 12 hours
- Duration: 7-10 days
- Infusion time: 30 minutes 1
This lower dose range is FDA-approved and appropriate when dealing with typical uropathogens like E. coli, K. pneumoniae, or P. mirabilis in patients without severe illness 1.
Severe UTI or Pyelonephritis
- Dose: 2 g IV every 12 hours
- Duration: 10 days
- Infusion time: 30 minutes 1
The 2024 European Association of Urology guidelines support this higher dosing for hospitalized patients with uncomplicated pyelonephritis requiring parenteral therapy, noting that while lower doses have been studied, higher doses are recommended 2. The FDA label confirms this 2 g every 12 hours regimen specifically for severe UTI 1.
Critical Dosing Adjustments
Renal Impairment
You must adjust doses when creatinine clearance ≤60 mL/min to prevent neurotoxicity 1:
- CrCl 30-60 mL/min: Reduce frequency to every 24 hours (maintain same individual dose)
- CrCl 11-29 mL/min: For severe UTI, reduce to 1 g every 24 hours
- CrCl <11 mL/min: For severe UTI, reduce to 500 mg every 24 hours
- Hemodialysis: 1 g on day 1, then 500 mg every 24 hours (give after dialysis) 1
Pseudomonas Coverage
If Pseudomonas aeruginosa is suspected or confirmed, do not use cefepime for UTI - the guidelines recommend 2 g every 8 hours for Pseudomonas pneumonia, but cefepime is not the preferred agent for Pseudomonas UTI 2, 1.
Important Clinical Caveats
Avoid cefepime for carbapenemase-producing organisms: Recent 2025 data demonstrates that cefepime fails clinically for KPC-producing E. coli UTI even when in vitro testing shows susceptibility 3. If carbapenem resistance is suspected or confirmed, choose ceftazidime/avibactam or other carbapenemase-stable agents instead 3, 4.
Neurotoxicity risk: This is the most serious adverse effect, occurring especially in elderly patients with unrecognized renal impairment who receive unadjusted doses. If confusion, myoclonus, seizures, or encephalopathy develop, discontinue cefepime immediately 1.
Guideline context: While the EAU guidelines list cefepime as an option for pyelonephritis, they emphasize that fluoroquinolones, aminoglycosides, and extended-spectrum cephalosporins/penicillins are all reasonable choices - the selection should be based on local resistance patterns 2. Cefepime's niche is when broader coverage is needed but you want to avoid carbapenems.
Pediatric Dosing (2 months to 16 years)
- Dose: 50 mg/kg every 12 hours (maximum not to exceed adult dose)
- Duration: Same as adults (7-10 days) 1
Clinical trials in children with serious UTI showed >95% favorable response rates with this regimen 5.